TESARO (NASDAQ:TSRO) will be issuing its quarterly earnings data after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of ($2.35) per share for the quarter.
TESARO (NASDAQ TSRO) opened at $60.74 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. TESARO has a 1-year low of $55.02 and a 1-year high of $190.40. The firm has a market cap of $3,311.31, a price-to-earnings ratio of -7.20 and a beta of 1.25.
TSRO has been the topic of several research reports. Morgan Stanley lowered their price objective on shares of TESARO from $165.00 to $156.00 and set an “overweight” rating on the stock in a report on Tuesday, January 16th. Jefferies Group restated a “hold” rating and set a $124.00 price objective on shares of TESARO in a report on Friday, November 3rd. Credit Suisse Group restated an “outperform” rating and set a $150.00 price objective (down previously from $190.00) on shares of TESARO in a report on Thursday, January 18th. Leerink Swann upgraded shares of TESARO from a “market perform” rating to an “outperform” rating in a report on Wednesday, November 15th. Finally, BidaskClub upgraded shares of TESARO from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $148.60.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. 40.50% of the stock is currently owned by corporate insiders.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.